Despite the significant resources dedicated to the development of monoclonal antibody
(mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited …

Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …

The ability of antibodies to exploit antigenic differences between normal and malignant
tissues and to exact a variety of antitumor responses offers significant advantages to …

Monoclonal antibodies are increasingly being used as protein therapeutics for cancer. They
offer very specific binding to target molecules on the surface of cancer cells, relatively few …

The use of antibody-based therapeutics has proven very promising for clinical applications
in cancer patients, with multiple examples of antibodies and antibody–drug conjugates …

Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses
to mAb therapy, however, are far from optimal, with many patients presenting native or …

Cancer immunotherapy has been at the forefront of therapeutic interventions for many
different tumor types over the last decade. While the discovery of immunotherapeutics …

The advent of monoclonal antibody (MAb) techniques has led to an explosion of ideas, in
vitro and in vivo animal studies, and clinical trials aimed at evaluating the use of antibodies …

The advent of hybridoma technology and genetic engineering has led to the design and
large-scale production of monoclonal antibodies (MAbs) and other biological …

Antibody drugs have become the mainstream of cancer treatment due to advances in cancer
biology and Ab engineering. However, several barriers to Ab therapy have also been …